Market Overview

Cytobank Awarded NIH Grant to Scale Its Cloud-Based Machine Learning Platform for Accelerating Immunotherapy Translational Research

Share:

Novel data analysis methods will automate biomarker discovery to
predict patient response in clinical trials

Cytobank has been awarded a $1.3M Phase II SBIR grant from the NIH to
scale and add more machine learning algorithms to its cloud-based
informatics platform. In use at many leading academic institutions and
the top ten global pharmaceutical companies, Cytobank's research
platform enables faster, more comprehensive analysis of the
high-dimensional single cell datasets captured in immunotherapy clinical
trials. There are greater than 1,000 active clinical trials for
immunotherapies in oncology alone.

Immunotherapies already extend the lives of patients with many different
types of cancer, but unfortunately, they only work for a minority of
patients. One key to deciphering which patients will respond, and
improving the therapies overall, is the discovery of biomarkers.
Cytobank's cloud-based platform analyzes very large data sets quickly
and makes collaboration between scientists easy.

Dr. Antoni Ribas, Director of the Tumor Immunology Program at UCLA's
Jonsson Comprehensive Cancer Center and the Chair of the Melanoma
Committee at SWOG, states, "The efficient identification of clinically
informative biomarkers is critical to the success of immunotherapy.
Single cell analysis technologies are generating larger and larger
datasets from the significant and growing number of combination clinical
trials. Informatics platforms like Cytobank are instrumental for quickly
mining these datasets and discovering putative biomarkers."

In addition to accelerating the pace at which biomarker discovery can
occur, Cytobank's unique capabilities enable the discovery of biomarkers
that may be missed with traditional analysis approaches or non
cloud-based platforms where collaboration across large datasets is
challenging. "In our research we have found that high-dimensional
machine learning-based analyses of clinical samples, like those enabled
by Cytobank, can often reveal important cell populations that are missed
with traditional manual analysis approaches," observes Dr. Stephen Oh of
Washington University School of Medicine in St. Louis. "It's crucial for
us to be as comprehensive and efficient as possible in our
investigations, which is why we prefer to use platforms like Cytobank."

Cytobank CEO David Craford comments, "We're honored that the NIH/NIGMS
has confidence in our platform, and I'm excited about the developments
we will make to help our customers develop new therapies and diagnostics
for improved patient care. The additions we plan to make with this grant
should give us the capability to increase the analysis capacity for
single cell data sets by 10-100X greater than what is possible today."

About Cytobank

Cytobank Inc. is a private, for-profit company founded by scientists
from Stanford University and based in Mountain View, California. We
currently have positions open at Careers
at Cytobank
and are interested in meeting investors that believe in
our mission to enable discovery from big data in immunology.

About the NIH SBIR Program

The National Institutes of Health (NIH), a part of the U.S. Department
of Health and Human Services, is the nation's medical research agency —
making important discoveries that improve health and save lives. The NIH
Small Business Innovation Research (SBIR) program funds early stage
small businesses that are seeking to commercialize innovative biomedical
technologies. This competitive program helps small businesses
participate in federal research and development, develop life-saving
technologies, and create jobs.

Research described in this release is supported by the National
Institute Of General Medical Sciences of the National Institutes of
Health under Award Number R44GM117914. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.

View Comments and Join the Discussion!